ACRS

Aclaris Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. Headquartered in Wayne, Pennsylvania, the company advances both small molecule and biologic therapeutic candidates targeting diseases affecting the skin and adjacent mucosal tissues. Aclaris develops its pipeline through two primary segments: dermatology and rheumatology. The company's lead programs include ATI-450, a MK2 inhibitor in development for oral treatment of rheumatoid arthritis and hidradenitis suppurativa, and ATI-1777, a soft JAK 1/3 inhibitor designed for dermatological conditions. In dermatology, Aclaris markets two FDA-approved topical medications: ESKATA (hydrogen peroxide) for seborrheic keratosis and RHOFADE (oxymetazoline hydrochloride) for persistent facial erythema associated with rosacea. The company employs approximately 100 people and maintains research collaborations with academic institutions and biotechnology partners. In recent developments, Aclaris has advanced multiple candidates through Phase 2 clinical trials and continues to expand its pipeline through internal research and strategic in-licensing agreements. The company utilizes a target-based drug discovery approach, focusing on kinase inhibition and inflammatory pathway modulation. Aclaris trades on the NASDAQ exchange under the ticker symbol ACRS and reports financial results as a publicly-traded entity subject to SEC regulations.